Biotech behind 2022’s largest local IPO delays norovirus vaccine

HilleVax Inc., the biotech that pulled off Boston’s largest IPO of 2022, is delaying its norovirus vaccine by several months. CEO Rob Hershbeg cited logistical issues as reason for the delay.